Optimal diagnosis and management of non-alcoholic fatty liver disease

[1] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49:197–211. CobbinaE AkhlaghiF Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters Drug Metab Rev 2017 49 197 211 10.1080/03602532.2017.1293683 Search in Google Scholar

[2] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021; 18:223–38. HuangDQ El-SeragHB LoombaR Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 2021 18 223 38 10.1038/s41575-020-00381-6 Search in Google Scholar

[3] Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J. 2020; 50:1038–47. HuangTD BeharyJ ZekryA Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management Intern Med J 2020 50 1038 47 10.1111/imj.14709 Search in Google Scholar

[4] Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. Clin Liver Dis (Hoboken). 2012; 1:99–103. PuriP SanyalAJ Nonalcoholic fatty liver disease: definitions, risk factors, and workup Clin Liver Dis (Hoboken) 2012 1 99 103 10.1002/cld.81 Search in Google Scholar

[5] Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20:47–85. SumidaY NakajimaA ItohY Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis World J Gastroenterol 2014 20 47 85 10.3748/wjg.v20.i2.475 Search in Google Scholar

[6] Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020; 5:362–73. NewsomePN SassoM DeeksJJ ParedesA BoursierJ ChanWK FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study Lancet Gastroenterol Hepatol 2020 5 362 73 10.1016/S2468-1253(19)30383-8 Search in Google Scholar

[7] Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: a review for clinicians. World J Hepatol. 2021; 13:1688–98. KalasMA ChavezL LeonM TaweesedtPT SuraniS Abnormal liver enzymes: a review for clinicians World J Hepatol 2021 13 1688 98 10.4254/wjh.v13.i11.1688863768034904038 Search in Google Scholar

[8] Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018; 53:362–76. SumidaY YonedaM Current and future pharmacological therapies for NAFLD/NASH J Gastroenterol 2018 53 362 76 10.1007/s00535-017-1415-1584717429247356 Search in Google Scholar

[9] Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J. 2019; 95:601–11. AmanullahI KhanYH AnwarI GulzarA MallhiTH RajaAA Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials Postgrad Med J 2019 95 601 11 10.1136/postgradmedj-2018-13636431434683 Search in Google Scholar

[10] Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013; 62:392–9. SirotaJC McFannK TargherG JohnsonRJ ChoncholM JalalDI Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey Metabolism 2013 62 392 9 10.1016/j.metabol.2012.08.013356504723036645 Search in Google Scholar

[11] Ryu S, Chang Y, Zhang Y, Kim SG, Cho J, Son HJ, et al. A cohort study of hyperuricemia in middle-aged South Korean men. Am J Epidemiol. 2012; 175:133–43. RyuS ChangY ZhangY KimSG ChoJ SonHJ A cohort study of hyperuricemia in middle-aged South Korean men Am J Epidemiol 2012 175 133 43 10.1093/aje/kwr29122156041 Search in Google Scholar

[12] Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011; 34:757–66. PettaS CammàC CabibiD Di MarcoV CraxìA Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease Aliment Pharmacol Ther 2011 34 757 66 10.1111/j.1365-2036.2011.04788.x21790685 Search in Google Scholar

[13] Park H, Park K-Y, Kim M, Park H-K, Hwang H-S. Association between serum uric acid level and non-alcoholic fatty liver disease. Asian Biomed (Res Rev News). 2022; 15:15–22. ParkH ParkK-Y KimM ParkH-K HwangH-S Association between serum uric acid level and non-alcoholic fatty liver disease Asian Biomed (Res Rev News) 2022 15 15 22 10.2478/abm-2022-0003 Search in Google Scholar

[14] Yoneda M, Thomas E, Sumida Y, Imajo K, Hyogo H, Fujii H, et al. Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Biochem. 2014; 47:1138–9. YonedaM ThomasE SumidaY ImajoK HyogoH FujiiH Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease Clin Biochem 2014 47 1138 9 10.1016/j.clinbiochem.2014.04.02624797484 Search in Google Scholar

[15] Rinella ME, Tacke F, Sanyal AJ, Anstee QM; Participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019; 70:1424–36. RinellaME TackeF SanyalAJ AnsteeQM Participants of the AASLD/EASL Workshop Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD Hepatology 2019 70 1424 36 10.1002/hep.3078231287572 Search in Google Scholar